Hyaluronan Conjugate for IL-6 Blockade in Pulmonary Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary inflammation, particularly those involving IL-6 blockade, rely on expensive antibody-based biologics, necessitating a cost-effective small-molecule-based therapeutic agent.
Innovation Solution
A hyaluronan conjugate with a specific disaccharide unit structure and a degree of substitution of 0.5% to 35% is administered to treat pulmonary inflammation, effectively blocking the IL-6-mediated cascade and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-based biologics are used for IL-6 blockade, then treatment effectiveness is improved, but cost increases significantly
Solution Approach 1:
The patent replaces expensive antibody-based biologics with a small-molecule hyaluronan conjugate that is cheaper to manufacture. The conjugate uses hyaluronan (a natural polymer) combined with a small molecule drug, creating a cost-effective alternative to protein-based biologics while maintaining therapeutic effectiveness for IL-6 blockade.
Solution Approach 2:
The invention creates a composite therapeutic agent by conjugating hyaluronan (a natural glycosaminoglycan) with a small-molecule drug. This composite structure combines the advantages of both components: the biocompatibility and targeting capability of hyaluronan with the potency and cost-effectiveness of small-molecule drugs, achieving effective IL-6 blockade at lower cost.
2Ease of manufacture
If small-molecule-based therapeutic agents are used, then cost is reduced, but treatment effectiveness may be compromised
Solution Approach 1:
The patent overcomes the limitations of small molecules by creating a hybrid conjugate structure. The hyaluronan component provides biological recognition and targeting properties, while the small-molecule component delivers potent pharmacological activity. This composite approach ensures treatment effectiveness comparable to biologics while maintaining the cost advantages of small molecules.
Solution Approach 2:
The invention modifies the parameters of small-molecule therapy by conjugating it to hyaluronan, thereby changing its pharmacokinetic and pharmacodynamic properties. The conjugation enhances the small molecule's ability to reach target sites, prolongs its action, and improves its overall therapeutic profile, ensuring effectiveness despite the use of a smaller, cheaper molecular structure.
Data Source
AI summary
Disclosed herein are hyaluronic acid (HA)-nimesulide conjugates having one or two disaccharide units.